Stereotaxis Reports Double-Digit Revenue Growth for 2025 Amidst New Catheter Launches

Stereotaxis has reiterated its double-digit revenue growth outlook for 2025, driven by the launch of new catheter products. CEO David Leo Fischel described 2025 as a pivotal year for the company, with a focus on advancing strategic innovations and demonstrating their commercial impact. The company's commercial momentum is expected to continue, driven by the launch of new products.

Stereotaxis Inc. (STXS) reported its second-quarter 2025 earnings, showcasing a significant revenue increase that surpassed analyst expectations. The company achieved a 95% year-over-year revenue growth, with revenue reaching $8.8 million, compared to the forecasted $7.75 million. The earnings per share (EPS) of -$0.05 also beat the forecasted -$0.07 by 28.57%.

Despite the positive earnings report, Stereotaxis' stock experienced a 2.67% decline in after-hours trading, closing at $2.19. This movement might be attributed to broader market trends or investor caution regarding the company’s future profitability and competitive pressures. The stock has delivered an 18.38% return over the past year, despite recent volatility.

Key takeaways from the earnings report include:

- Revenue Growth: The company achieved a 95% year-over-year revenue growth in Q2 2025.
- System Revenue: System revenue was $3 million, with recurring revenue at $5.8 million.
- Gross Margin: Gross margin was 52%, with recurring revenue gross margin at 68% and system gross margin at 22%.
- Operating Loss: The company reported an operating loss of $4 million.
- Cash and Cash Equivalents: Cash and cash equivalents increased to $18.8 million post-financing.

Stereotaxis is preparing for the full launch of new technologies, including the Genesis X robotic system and the MAGIC ablation catheter. The company expects the upcoming launch of the Genesis X to drive further growth, with orders projected to outpace current Genesis orders. The CE Mark approval for the Genesis X robotic system and the MAGIC ablation catheter positions the company well within the competitive landscape of the electrophysiology market.

The CEO, David Fischel, emphasized the significance of the current year, stating, "We’ve described this year as a pivotal milestone rich year." He highlighted the company’s innovation strategy, which rests on four primary pillars, and expressed optimism about launching new technologies with a focus on accelerating growth.

Analyst consensus remains bullish, with price targets ranging from $4.00 to $5.00, suggesting significant upside potential. The stock remains within its 52-week range, between $1.54 and $2.716.

References
[1] https://za.investing.com/news/transcripts/earnings-call-transcript-stereotaxis-q2-2025-revenue-beats-forecasts-93CH-3828395